Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Core Insights - Aclarion, Inc. has launched the multi-center CLUE Trial to assess how often surgeons alter their treatment plans after receiving Nociscan data, aiming to provide real-world evidence of its value in treating chronic low back pain [1][2] - The CLUE Trial is designed to complement the earlier launched CLARITY trial, which aims to demonstrate improved surgical outcomes when Nociscan data is included in decision-making [2][3] - The company emphasizes the importance of evidence-based approaches in advocating for insurance coverage of Nociscan, drawing parallels to successful strategies used in other medical fields [3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to differentiate between painful and non-painful discs [4] - Nociscan is the first evidence-supported SaaS platform that aids physicians in identifying the source of low back pain through non-invasive methods [4] - The company aims to optimize treatment strategies by providing critical insights into the location of pain, thereby addressing a significant healthcare challenge [4]